Glenmark Generics (GGI), the US-based arm of Glenmark Generics (GGL),, declared the United States Food and Drug Administration (USFDA) has granted nod for 3 Abbreviated New Drug Applications (ANDA).

Final ANDA authorizations were bagged for Indomethacin 25 mg and 50 mg caps, USP and Sulfamethoxazole and Trimethoprim double and single strength tabs.

These medications are presently available and the company has started shipping from its plant based in New Jersey.

On December 20, Glenmark Generics pocketed final nod from the USFDA for Felodipine extended release tabs, which are available in potencies of 2.5 mg, 5 mg and 10 mg.

Today, the stock of the company opened at Rs 351.50 on the BSE.

At 02:43 p. m., the stock of the company stood at Rs 351.05, up 0.4% on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 389.75 and a low of Rs 230 on BSE.

The total volume of the shares traded stood at 49,760.

Current EPS & P/E ratio stood at 17.18 and 20.46 respectively.